SE9301830D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9301830D0
SE9301830D0 SE19939301830A SE9301830A SE9301830D0 SE 9301830 D0 SE9301830 D0 SE 9301830D0 SE 19939301830 A SE19939301830 A SE 19939301830A SE 9301830 A SE9301830 A SE 9301830A SE 9301830 D0 SE9301830 D0 SE 9301830D0
Authority
SE
Sweden
Prior art keywords
new compounds
improved
omeprazole
enantiomer
manufacture
Prior art date
Application number
SE19939301830A
Other languages
English (en)
Inventor
Lennart *Lindberg Per
P O *Von Unge Sverker
Original Assignee
Ab Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390088&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9301830(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ab Astra filed Critical Ab Astra
Priority to SE19939301830A priority Critical patent/SE9301830D0/sv
Publication of SE9301830D0 publication Critical patent/SE9301830D0/sv
Priority to IS4161A priority patent/IS1854B/is
Priority to TW083104255A priority patent/TW389761B/zh
Priority to HR940307A priority patent/HRP940307B1/xx
Priority to LTIP1941A priority patent/LT3287B/lt
Priority to IL10968494A priority patent/IL109684A/en
Priority to ZA943557A priority patent/ZA943557B/xx
Priority to DZ940055A priority patent/DZ1785A1/fr
Priority to MA23521A priority patent/MA23210A1/fr
Priority to DE69435221T priority patent/DE69435221D1/de
Priority to SI9420085A priority patent/SI22752B/sl
Priority to SI9420002A priority patent/SI9420002B/sl
Priority to PL94307261A priority patent/PL178994B1/pl
Priority to ES00108479T priority patent/ES2326404T3/es
Priority to ES00108480.5T priority patent/ES2326405T5/es
Priority to CA002337581A priority patent/CA2337581A1/en
Priority to EP00108480.5A priority patent/EP1020461B2/en
Priority to DK00108479T priority patent/DK1020460T3/da
Priority to PT00108480T priority patent/PT1020461E/pt
Priority to MYPI94001349A priority patent/MY121192A/en
Priority to UA95018075A priority patent/UA60289C2/uk
Priority to CN94190335A priority patent/CN1055469C/zh
Priority to RU95105587A priority patent/RU2137766C1/ru
Priority to DE0652872T priority patent/DE652872T1/de
Priority to DE69435220T priority patent/DE69435220D1/de
Priority to CA002139653A priority patent/CA2139653C/en
Priority to DK00108480.5T priority patent/DK1020461T4/en
Priority to TNTNSN94058A priority patent/TNSN94058A1/fr
Priority to DE69426254T priority patent/DE69426254T2/de
Priority to PCT/SE1994/000509 priority patent/WO1994027988A1/en
Priority to CZ1995202A priority patent/CZ287876B6/cs
Priority to SG1996008770A priority patent/SG49283A1/en
Priority to KR1019950700365A priority patent/KR100337274B1/ko
Priority to YU31494A priority patent/YU49065B/sh
Priority to PT94917244T priority patent/PT652872E/pt
Priority to SK101-95A priority patent/SK282524B6/sk
Priority to HU9500247A priority patent/HU226824B1/hu
Priority to DK94917244T priority patent/DK0652872T3/da
Priority to AT94917244T priority patent/ATE197452T1/de
Priority to EP00108479A priority patent/EP1020460B1/en
Priority to ES94917244T priority patent/ES2099047T3/es
Priority to PT00108479T priority patent/PT1020460E/pt
Priority to US08/256,174 priority patent/US5693818A/en
Priority to EP94917244A priority patent/EP0652872B1/en
Priority to NZ266915A priority patent/NZ266915A/en
Priority to JP50055395A priority patent/JP3549111B2/ja
Priority to AU69024/94A priority patent/AU676337C/en
Priority to SA94140756A priority patent/SA94140756B1/ar
Priority to SA05260103A priority patent/SA05260103B1/ar
Priority to EE9400363A priority patent/EE03157B1/xx
Priority to LVP-94-266A priority patent/LV11034B/en
Priority to US08/376,512 priority patent/US5714504A/en
Priority to NO950263A priority patent/NO307378B1/no
Priority to FI950377A priority patent/FI117755B/sv
Priority to US08/833,962 priority patent/US5877192A/en
Priority to GR970300012T priority patent/GR970300012T1/el
Priority to HK98109228A priority patent/HK1008330A1/xx
Priority to CN99118539A priority patent/CN1107503C/zh
Priority to US09/419,456 priority patent/US6143771A/en
Priority to US09/690,044 priority patent/US6875872B1/en
Priority to HK00107520.4A priority patent/HK1028045A1/xx
Priority to HK00107518.8A priority patent/HK1028044A1/xx
Priority to GR20010400191T priority patent/GR3035365T3/el
Priority to CY0100010A priority patent/CY2224B1/xx
Priority to JP2003317639A priority patent/JP4039999B2/ja
Priority to JP2003317637A priority patent/JP3959056B2/ja
Priority to US11/002,982 priority patent/US20060004057A1/en
Priority to FI20070002A priority patent/FI20070002A/sv
Priority to US11/679,264 priority patent/US20080312449A1/en
Priority to CL2009000805A priority patent/CL2009000805A1/es
Priority to US12/551,828 priority patent/US20100222591A1/en
Priority to NO2011009C priority patent/NO2011009I1/no
Priority to LU91870C priority patent/LU91870I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
SE19939301830A 1993-05-28 1993-05-28 New compounds SE9301830D0 (sv)

Priority Applications (73)

Application Number Priority Date Filing Date Title
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds
IS4161A IS1854B (is) 1993-05-28 1994-05-06 Aðferð til að útbúa ljósfræðilega hrein Na+, Mg2+, Li+, K+ eða Ca2+ sölt (-)-5-metoxý-2-[[(4-metoxý-3,5-dímetýl-2-pýridínýl)metýl]súlfinýl]-1H-bensimídasóls og milliefnasamband.
TW083104255A TW389761B (en) 1993-05-28 1994-05-11 Omeprazole and its alkaline salts with high optically purity, their pharmaceutical compositions, process for preparation including their intermediates and application in pharmaceuticals
HR940307A HRP940307B1 (en) 1993-05-28 1994-05-17 New compounds
LTIP1941A LT3287B (en) 1993-05-28 1994-05-18 Optical pure compounds, a process for their preparation and their use
IL10968494A IL109684A (en) 1993-05-28 1994-05-19 Optically pure crystalline salts of the (-) - an enantiomer of omeprazole, a process for their preparation and pharmaceutical preparations containing them
ZA943557A ZA943557B (en) 1993-05-28 1994-05-23 Highly optical pure benzimidazoles and salts thereof
DZ940055A DZ1785A1 (fr) 1993-05-28 1994-05-25 Nouveaux composés.
MA23521A MA23210A1 (fr) 1993-05-28 1994-05-26 Nouveaux composes
DE69435221T DE69435221D1 (de) 1993-05-28 1994-05-27 Magnesiumsalz des (-)-Enantiomers von Omeprazol und dessen Verwendung
SI9420085A SI22752B (sl) 1993-05-28 1994-05-27 Optično čiste soli piridinilmetil sulfinil-1H-benzimidazolovih spojin
SI9420002A SI9420002B (sl) 1993-05-28 1994-05-27 Optično čiste soli piridinilmetil sulfinil-1H-benzimidazolovih spojin
PL94307261A PL178994B1 (pl) 1993-05-28 1994-05-27 Optycznie czyste sole zwiazków pirydynylometylosulfinylo-1H-benzimidazolu i srodek farmaceutyczny je zawierajacy PL PL PL PL PL PL PL
ES00108479T ES2326404T3 (es) 1993-05-28 1994-05-27 Sal sodica del enantiomero (-) de omeprazol.
ES00108480.5T ES2326405T5 (es) 1993-05-28 1994-05-27 Sal de magnesio del enantiómero(-) del omeprazol y su uso
CA002337581A CA2337581A1 (en) 1993-05-28 1994-05-27 Optically pure salts of pyridinylmethyl sulfinyl-1h-benzimidazole compounds and intermediates in the preparation therefor
EP00108480.5A EP1020461B2 (en) 1993-05-28 1994-05-27 Magnesium salt of the (-)-enantiomer of omeprazole and its use
DK00108479T DK1020460T3 (da) 1993-05-28 1994-05-27 Natriumsalt af (-)enantiomeren af omeprazol
PT00108480T PT1020461E (pt) 1993-05-28 1994-05-27 Sal de magnésio do enantiómero (-) de omeprazole
MYPI94001349A MY121192A (en) 1993-05-28 1994-05-27 New compounds.
UA95018075A UA60289C2 (uk) 1993-05-28 1994-05-27 Оптично чисті солі (-)-5-метокси-2-[[(4-метокси-3,5-диметил-2-піридиніл)метил]сульфініл]-1h-бензімідазолу, спосіб їх одержання, проміжні сполуки та фармацевтична композиція
CN94190335A CN1055469C (zh) 1993-05-28 1994-05-27 旋光纯的吡啶甲基亚磺酰基－1h－苯并咪唑类化合物的盐、及其制法和应用
RU95105587A RU2137766C1 (ru) 1993-05-28 1994-05-27 Оптически чистые na+, mg2+, li+, k+ или са2+ соли (-)-5-метокси-2[[(4-метокси-3,5-диметил-2-пиридинил)метил] сульфинил]-1h-бензимидазола, способ их получения, фармкомпозиция на их основе и промежуточное соединение
DE0652872T DE652872T1 (de) 1993-05-28 1994-05-27 Optisch reine salze von pyridinylmethylsulfinyl-1h-benzimidazole-derivaten.
DE69435220T DE69435220D1 (de) 1993-05-28 1994-05-27 Das Natrium Salz des (-)-Enantiomer von Omeprazole
CA002139653A CA2139653C (en) 1993-05-28 1994-05-27 Optically pure salts of pyridinylmethyl sulfinyl-ih- benzimidazole compounds
DK00108480.5T DK1020461T4 (en) 1993-05-28 1994-05-27 The magnesium salt of the (-) enantiomer of omeprazole and the use of this
TNTNSN94058A TNSN94058A1 (fr) 1993-05-28 1994-05-27 Nouveaux composes
DE69426254T DE69426254T2 (de) 1993-05-28 1994-05-27 Optisch reines magnesium-salz eines pyridinylmethylsulfinyl-1h-benzimidazole-derivats
PCT/SE1994/000509 WO1994027988A1 (en) 1993-05-28 1994-05-27 Optically pure salts of pyridinylmethyl sulfinyl-ih-benzimidazole compounds
CZ1995202A CZ287876B6 (cs) 1993-05-28 1994-05-27 Opticky čistý pyridylmethylsulfinyl-1H-benzimidazolový derivát, způsob jeho výroby, farmaceutický prostředek s jeho obsahem a meziprodukt pro jeho výrobu
SG1996008770A SG49283A1 (en) 1993-05-28 1994-05-27 New compounds
KR1019950700365A KR100337274B1 (ko) 1993-05-28 1994-05-27 피리딘메틸술피닐-1h-벤즈이미다졸화합물의광학적으로순수한염
YU31494A YU49065B (sh) 1993-05-28 1994-05-27 Omeprazol enantiomeri, postupak za njihovo dobijanje, farmaceutski proizvodi i njihova upotreba u medicini
PT94917244T PT652872E (pt) 1993-05-28 1994-05-27 Sal de magnesio do composto piridinil metil sulfinil-1h-benzimidazole opticamente puro
SK101-95A SK282524B6 (sk) 1993-05-28 1994-05-27 Opticky čisté soli (-)-enantioméru pyridylmetylsulfinyl-1H- benzimidazolových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty na ich prípravu
HU9500247A HU226824B1 (en) 1993-05-28 1994-05-27 Optically active salts of pyridinyl-methyl-sulfinyl-1h-benzimidazol derivatives, pharmaceutical compositions containing them and process for producing them
DK94917244T DK0652872T3 (da) 1993-05-28 1994-05-27 Optisk rent magnesiumsalt af pyridinylmethylsulfinyl-1H-benzimidazolforbindelse
AT94917244T ATE197452T1 (de) 1993-05-28 1994-05-27 Optisch reines magnesium-salz eines pyridinylmethylsulfinyl-1h-benzimidazole-deriva s
EP00108479A EP1020460B1 (en) 1993-05-28 1994-05-27 The sodium salt of the (-)-enantiomer of omeprazole
ES94917244T ES2099047T3 (es) 1993-05-28 1994-05-27 Sal de magnesio opticamente pura de un compuesto de piridinilmetilsulfinil-1h-bencimidazol.
PT00108479T PT1020460E (pt) 1993-05-28 1994-05-27 Sal de sódio do enantiómero (-) de omeprazole
US08/256,174 US5693818A (en) 1993-05-28 1994-05-27 Process for preparing pure salts of pyridinylmethyl-sulfinyl-1H-benzimidazole
EP94917244A EP0652872B1 (en) 1993-05-28 1994-05-27 Optically pure magnesium -salt of pyridinylmethyl sulfinyl-1h-benzimidazole compound
NZ266915A NZ266915A (en) 1993-05-28 1994-05-27 Optically pure salts of (+)- and (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl] -sulphinyl]-1h-benzimidazole; pharmaceutical compositions (omeprazole)
JP50055395A JP3549111B2 (ja) 1993-05-28 1994-05-27 新規な化合物
AU69024/94A AU676337C (en) 1993-05-28 1994-05-27 Optically pure salts of pyridinylmethyl sulfinyl-IH- benzimidazole compounds
SA94140756A SA94140756B1 (ar) 1993-05-28 1994-06-04 ملح magnesium نقي ضوئياً لمركب pyridinylmethyl sulfinyl- 1H- benzimidazole
SA05260103A SA05260103B1 (ar) 1993-05-28 1994-06-04 ملح الصوديوم للمتشاكل -(-) للأومبرازول
EE9400363A EE03157B1 (et) 1993-05-28 1994-11-17 Omeprasooli enantiomeerid, nende valmistamise protsess ja neid sisaldavad ravimpreparaadid
LVP-94-266A LV11034B (en) 1993-05-28 1994-12-30 Optically pure salts of pyridinilmethyl sulfinyl-1h-benzimidazole compounds
US08/376,512 US5714504A (en) 1993-05-28 1995-01-23 Compositions
NO950263A NO307378B1 (no) 1993-05-28 1995-01-24 Optisk rene salter av pyridinylmetylsulfinyl-1H- benzimidazolforbindelser, fremgangsmåte for deres fremstilling, farmasøytisk preparat inneholdende slike forbindelser og deres anvendelse samt mellomprodukter
FI950377A FI117755B (sv) 1993-05-28 1995-01-27 Förfarande för framställning av ett terapeutiskt aktivt, optiskt rent natrium- eller magnesiumsalt av pyridinylmetylsulfinyl-1H-bensimidazolförening
US08/833,962 US5877192A (en) 1993-05-28 1997-04-11 Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
GR970300012T GR970300012T1 (en) 1993-05-28 1997-05-30 Optically pure salts of pyridinylmethyl sulfinyl-1h-benzimidazole compounds.
HK98109228A HK1008330A1 (en) 1993-05-28 1998-07-17 Optically pure magnesium-salt of pyridinylmethyl sulfinyl-1h-benzimidazole compound
CN99118539A CN1107503C (zh) 1993-05-28 1999-09-03 一种旋光纯化合物的药用
US09/419,456 US6143771A (en) 1993-05-28 1999-10-15 Compounds
US09/690,044 US6875872B1 (en) 1993-05-28 2000-10-16 Compounds
HK00107520.4A HK1028045A1 (en) 1993-05-28 2000-11-23 The sodium salt of the (-)-enantiomer of omeprazole
HK00107518.8A HK1028044A1 (en) 1993-05-28 2000-11-23 Magnesium salt of the (-)-enantiomer of omeprazole and its use
GR20010400191T GR3035365T3 (en) 1993-05-28 2001-02-05 Optically pure salts of pyridinylmethyl sulfinyl-1h-benzimidazole compounds.
CY0100010A CY2224B1 (en) 1993-05-28 2001-05-22 Optically pure salts of pyridinylmethyl sulfinyl-1H-benzimidazole compounds
JP2003317639A JP4039999B2 (ja) 1993-05-28 2003-09-10 新規な化合物の製造方法
JP2003317637A JP3959056B2 (ja) 1993-05-28 2003-09-10 新規な化合物
US11/002,982 US20060004057A1 (en) 1993-05-28 2004-12-01 New compounds
FI20070002A FI20070002A (sv) 1993-05-28 2007-01-02 Optiskt rena salter av pyridinylmetylsulfinyl-1H-bensimidazolföreningar
US11/679,264 US20080312449A1 (en) 1993-05-28 2007-02-27 New Compounds
CL2009000805A CL2009000805A1 (es) 1993-05-28 2009-04-02 Composicion farmaceutica que comprende a una sal sodica del enantiomero (-) de 5-metoxi-2[[(4-metoxi-3,5-dimetil-2-piridinil)metil]sulfinil]-1h-bencimidazol ((-)-omeprazol); y su uso en la inhibicion de la secrecion de acido gastrico y para tratar enfermedades inflamatorias gastrointestinales. (divisional solicitud 3570-00).
US12/551,828 US20100222591A1 (en) 1993-05-28 2009-09-01 New Compounds
NO2011009C NO2011009I1 (no) 1993-05-28 2011-06-07 Naproksen- og esomeprazoltabletter med modifisert frisetting
LU91870C LU91870I2 (fr) 1993-05-28 2011-09-19 Une combinaison de produit comprenant du naproxèneet un sel de magnésium d'esomeprazole

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds

Publications (1)

Publication Number Publication Date
SE9301830D0 true SE9301830D0 (sv) 1993-05-28

Family

ID=20390088

Family Applications (1)

Application Number Title Priority Date Filing Date
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds

Country Status (43)

Country Link
US (5) US5693818A (sv)
EP (3) EP1020460B1 (sv)
JP (3) JP3549111B2 (sv)
KR (1) KR100337274B1 (sv)
CN (2) CN1055469C (sv)
AT (1) ATE197452T1 (sv)
CA (2) CA2139653C (sv)
CL (1) CL2009000805A1 (sv)
CY (1) CY2224B1 (sv)
CZ (1) CZ287876B6 (sv)
DE (4) DE69426254T2 (sv)
DK (3) DK0652872T3 (sv)
DZ (1) DZ1785A1 (sv)
EE (1) EE03157B1 (sv)
ES (3) ES2099047T3 (sv)
FI (2) FI117755B (sv)
GR (2) GR970300012T1 (sv)
HK (3) HK1008330A1 (sv)
HR (1) HRP940307B1 (sv)
HU (1) HU226824B1 (sv)
IL (1) IL109684A (sv)
IS (1) IS1854B (sv)
LT (1) LT3287B (sv)
LU (1) LU91870I2 (sv)
LV (1) LV11034B (sv)
MA (1) MA23210A1 (sv)
MY (1) MY121192A (sv)
NO (2) NO307378B1 (sv)
NZ (1) NZ266915A (sv)
PL (1) PL178994B1 (sv)
PT (3) PT1020461E (sv)
RU (1) RU2137766C1 (sv)
SA (2) SA05260103B1 (sv)
SE (1) SE9301830D0 (sv)
SG (1) SG49283A1 (sv)
SI (2) SI22752B (sv)
SK (1) SK282524B6 (sv)
TN (1) TNSN94058A1 (sv)
TW (1) TW389761B (sv)
UA (1) UA60289C2 (sv)
WO (1) WO1994027988A1 (sv)
YU (1) YU49065B (sv)
ZA (1) ZA943557B (sv)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
KR100384960B1 (ko) 1994-07-08 2003-08-21 아스트라제네카 악티에볼라그 다단위정제투여형i
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CA2310585C (en) * 1997-12-08 2005-08-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel administration form comprising an acid-labile active compound
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
ATE526022T1 (de) * 1998-04-20 2011-10-15 Eisai R&D Man Co Ltd Stabilisierte zusammenstellungen die benzimidazole enthalten
EP1105387B1 (en) 1998-08-10 2003-01-29 Winston Pharmateuticals LLC Prodrugs of proton pump inhibitors
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
ES2222754T3 (es) 1998-11-18 2005-02-01 Astrazeneca Ab Procedimiento quimico mejorado, y formulacion farmaceutica.
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
EP1191948A2 (en) * 1999-06-11 2002-04-03 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
EP1595879A3 (en) * 1999-08-26 2010-01-27 aaiPharma Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) * 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
DE60016617T2 (de) * 1999-10-01 2005-04-28 Natco Pharma Ltd., Banjara Hills Magensaftresistente gelartige weichkapsel
US7220762B1 (en) * 1999-10-20 2007-05-22 Eisai R&D Management Co., Ltd. Methods for stabilizing benzimidazole compounds
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
DE60015607T2 (de) 2000-02-24 2005-11-10 Kopran Research Laboratories Ltd. Oral verabreichbare säurebeständige geschwürbehandelnde benzimidazolderivate
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
AU5248601A (en) * 2000-05-15 2001-11-26 Ranbaxy Laboratories Limited Novel amorphous form of omeprazole salts
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
AU2003204233B8 (en) * 2000-08-04 2008-06-26 Bernard Charles Sherman Magnesium salt of S-omeprazole
CA2417311C (en) 2000-08-04 2012-07-10 Takeda Chemical Industries, Ltd. Crystalline alkali metal salts of lansoprazole and their production and use
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
JP2004536034A (ja) * 2001-01-08 2004-12-02 ネオルクス コーポレイション 治療的および診断的化合物、組成物および方法
US7064214B2 (en) * 2001-04-13 2006-06-20 Apsinterm Llc Methods of preparing sulfinamides and sulfoxides
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
CA2445513A1 (en) 2001-09-18 2003-03-27 Zeria Pharmaceutical Co., Ltd. Benzimidazole derivatives
EP1469839A2 (en) * 2002-01-25 2004-10-27 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
DE60314105T2 (de) 2002-03-05 2008-01-24 Astrazeneca Ab Alkylammoniumsalze von omeprazol und esomeprazol
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
US6894066B2 (en) * 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
ES2263028T3 (es) * 2002-07-19 2006-12-01 Winston Pharmaceuticals Llc Derivados de bencimidazol y su uso como profarmacos de inhibidores de bomba de proton.
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
CA2493618A1 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
CA2501424A1 (en) 2002-08-30 2004-03-11 Dr. Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
CA2771725C (en) 2002-10-16 2015-08-18 Takeda Pharmaceutical Company Limited Solid preparation comprising a non-toxic base and a proton pump inhibitor
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
EA200500673A1 (ru) * 2002-10-22 2005-12-29 Рэнбакси Лабораториз Лимитед Аморфная форма соли эзомепразола, способ ее получения и фармацевтическая композиция на её основе
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
AR042278A1 (es) 2002-12-06 2005-06-15 Altana Pharma Ag Un procedimiento para la preparacion de (s) - pantoprazol
BRPI0310118B1 (pt) 2002-12-06 2015-10-20 Altana Pharma Ag processo para a preparação de inibidores de bomba de próton (ppi) opticamente puro possuindo uma estrutura de sulfinila
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20060247277A1 (en) * 2003-02-28 2006-11-02 Yatendra Kumar Polymorphs of s-omeprazole
AU2003238671A1 (en) * 2003-04-10 2004-11-01 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
EP1633736A1 (en) * 2003-05-05 2006-03-15 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
WO2004099182A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Zinc salt of (s)-omeprazole
PL379542A1 (pl) * 2003-07-15 2006-10-02 Allergan, Inc. Sposób wytwarzania izomerycznie czystych proleków inhibitorów pompy protonowej
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005007117A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
TWI398273B (zh) * 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
SI1651217T1 (sl) * 2003-07-23 2008-08-31 Nycomed Gmbh Alkalne soli inhibitorjev protonske ÄŤrpalke
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
WO2005011637A1 (ja) * 2003-08-04 2005-02-10 Eisai Co., Ltd. 用時分散型製剤
SE0302381D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
EP1663173A1 (en) * 2003-09-25 2006-06-07 Natco Pharma Limited Enteric soft gelatin capsule containing esomeprazole and method of preparation
WO2005072079A2 (en) 2003-09-26 2005-08-11 Alza Coporation Drug coating providing high drug loading and methods for providing the same
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005034924A1 (en) * 2003-10-14 2005-04-21 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
JP2007523164A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターに関連する化合物の静脈内投与のための方法および組成物
WO2005082337A2 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
EP1740571B1 (en) 2004-04-28 2009-07-29 Hetero Drugs Limited A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
DE602004025386D1 (de) 2004-05-28 2010-03-18 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden
US20080249134A1 (en) * 2004-06-24 2008-10-09 Ursula Hohlneicher New Esomeprazole Sodium Salt Crystal Modification
CN103772360A (zh) * 2004-06-24 2014-05-07 阿斯利康(瑞典)有限公司 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
KR100847635B1 (ko) * 2004-08-06 2008-07-21 에자이 알앤드디 매니지먼트 가부시키가이샤 벤즈이미다졸 유도체와 아민과의 염
CA2575718C (en) 2004-08-06 2010-12-14 Eisai R & D Management Co., Ltd. Salts of benzimidazole derivative with amines and process for manufacturing the same
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
CA2597632C (en) 2005-03-25 2012-05-15 Livzon Pharmaceutical Group Inc. Substituted sulfoxide compounds, methods for preparing the same and use thereof
KR20080007508A (ko) * 2005-05-06 2008-01-21 그렌마크 파머수티칼스 엘티디. 에소메프라졸 스트론튬염, 그것의 제조방법 및 그것을함유하는 약제학적 조성물
JP2008545627A (ja) * 2005-05-09 2008-12-18 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 腎結石症を治療する方法
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
EP1891043A1 (en) * 2005-06-15 2008-02-27 Hetero Drugs Limited Amorphous esomeprazole hydrate
KR100641534B1 (ko) * 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
CA2617248C (en) * 2005-08-03 2015-09-29 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
CA2631919A1 (en) 2005-12-05 2007-06-14 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CA2631459A1 (en) * 2005-12-28 2007-07-05 Union Quimico Farmaceutica, S.A. A process for the preparation of the (s)-enantiomer of omeprazole
US8063074B2 (en) * 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
ES2355164T3 (es) * 2006-06-07 2011-03-23 Astrazeneca Ab Nuevo método para la preparación de sales de amonio de esomeprazol.
US7863330B2 (en) * 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
AU2006345861B2 (en) 2006-07-05 2012-07-12 Lupin Limited Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds
WO2008012621A2 (en) 2006-07-25 2008-01-31 Vecta, Ltd. Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
KR20090103879A (ko) * 2006-11-13 2009-10-01 다케다 파마슈티칼스 노쓰 어메리카, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
US20090042887A1 (en) * 2007-01-19 2009-02-12 Tap Pharmaceutical Products, Inc. Methods for Preventing or Reducing the Number of Gout Flares Using Xanthine Oxidoreductase Inhibitors and Anti-Inflammatory Agents
WO2008092939A2 (en) * 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
NZ579136A (en) 2007-02-21 2012-05-25 Cipla Ltd Process for the preparation of esomeprazole magnesium dihydrate
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (en) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
ATE534643T1 (de) * 2007-06-07 2011-12-15 Aurobindo Pharma Ltd Verbessertes verfahren zur herstellung eines optisch aktiven protonenpumpenhemmers
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
EP2106397B1 (en) 2007-09-25 2011-11-16 Hetero Drugs Limited A process for preparation of enantiomerically pure esomeprazole
EP2195309A4 (en) 2007-10-08 2013-04-24 Hetero Drugs Ltd SALT POLYMORPHS OF THE ESOMEPRAZOLE
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
EP2252274A4 (en) 2008-02-20 2011-05-11 Univ Missouri COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009145368A1 (en) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent
EP2143722A1 (en) * 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
EP2264024A1 (en) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Process for the preparation of enantiomerically enriched proton pump inhibitors
US8354541B2 (en) 2008-11-18 2013-01-15 Hetero Research Foundation Optical purification of esomeprazole
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
KR20120030106A (ko) 2009-06-25 2012-03-27 아스트라제네카 아베 Ｎｓａｉｄ-연관된 궤양의 발생 위험이 있는 환자의 치료 방법
AU2010266026B2 (en) * 2009-06-25 2014-08-07 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Method for treating a patient in need of aspirin therapy
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US8748619B2 (en) 2009-11-12 2014-06-10 Hetero Research Foundation Process for the resolution of omeprazole
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2519229A2 (en) 2009-12-29 2012-11-07 Novartis AG New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
CA2789298A1 (en) 2010-02-12 2011-08-18 Esteve Quimica, S.A. Preparation process of the sodium salt of esomeprazole
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
KR101797936B1 (ko) 2010-09-10 2017-11-15 다케다 파마슈티칼스 유에스에이, 인코포레이티드 테오필린과 페북소스타트의 병용 치료 방법
CN102816149B (zh) * 2011-06-10 2015-05-13 上海汇伦生命科技有限公司 一种高对映选择性合成(s)-奥美拉唑及其盐的制备方法
CN102807561A (zh) * 2011-06-21 2012-12-05 寿光富康制药有限公司 S-奥美拉唑铝盐及其制备方法和应用
CN102850323A (zh) * 2011-06-30 2013-01-02 秦引林 一种埃索美拉唑钠的精制方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN102911158B (zh) * 2011-07-31 2015-07-22 连云港润众制药有限公司 埃索美拉唑镁的晶型
WO2013081566A1 (en) 2011-11-25 2013-06-06 Mahmut Bilgic A formulation comprising benzimidazole
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2013108068A1 (en) 2012-01-21 2013-07-25 Jubilant Life Sciences Limited Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers
CN103420978A (zh) * 2012-05-15 2013-12-04 上海医药工业研究院 一种苯并咪唑类化合物的镁盐的制备方法
CN102657622A (zh) * 2012-05-17 2012-09-12 康普药业股份有限公司 一种含有埃索美拉唑钠的冻干粉针剂的制备工艺
CN102964335B (zh) * 2012-11-13 2014-06-25 凌元敏 一种埃索美拉唑钠化合物及其制备方法和用途
CN103159737B (zh) * 2013-04-12 2014-03-19 四川省惠达药业有限公司 一种埃索美拉唑钠化合物及药物组合物
EP3065720A1 (en) 2013-11-04 2016-09-14 Capsugel Belgium NV Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
WO2015155281A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CN104045627A (zh) * 2014-05-21 2014-09-17 丽珠医药集团股份有限公司 一种奥美拉唑纯化方法
CN104530003A (zh) * 2014-06-10 2015-04-22 广东东阳光药业有限公司 吡啶甲基亚磺酰基-1h-苯并咪唑类化合物的盐的制备方法
EP2980086B1 (en) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of esomeprazole (S)-binol complex
JP6548336B2 (ja) 2014-12-26 2019-07-24 国立大学法人 東京大学 光学活性のプロトンポンプ阻害化合物の製造方法
EP3064495B1 (en) 2015-03-06 2016-12-14 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of optically pure esomeprazole
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN105924430A (zh) * 2016-06-27 2016-09-07 杭州富阳伟文环保科技有限公司 一种埃索美拉唑钠的精制方法
WO2018191210A1 (en) * 2017-04-11 2018-10-18 Mclaughlin Gormley King Company Sabadilla oil and uses thereof
CN108409714A (zh) * 2018-03-29 2018-08-17 成都通德药业有限公司 埃索美拉唑、埃索美拉唑盐及埃索美拉唑镁的制备方法
CA3146660A1 (en) * 2019-07-16 2021-01-21 Kindred Biosciences, Inc. Equine esomeprazole formulations and methods of use
WO2021039800A1 (ja) 2019-08-29 2021-03-04 学校法人東京理科大学 スルホキシド化合物のエナンチオマー調製方法及びエナンチオマー調製システム
RU2726320C1 (ru) * 2020-02-09 2020-07-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) Способ определения примесных компонентов омепразола
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4636085A (en) * 1982-03-16 1987-01-13 Mapro Inc. Apparatus for removing volatiles from plastic materials delivered to an extrusion or injection molding machine
SE8204879D0 (sv) * 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US4445708A (en) * 1983-05-09 1984-05-01 General Motors Corporation Energy absorbing steering column for vehicles
SE8403179D0 (sv) * 1984-06-13 1984-06-13 Haessle Ab New compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
JPH08509736A (ja) * 1993-04-27 1996-10-15 セプラコー，インコーポレイテッド 光学的に純粋な（−）パントプラゾールを用いる胃の疾患治療の方法と組成
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
KR100384960B1 (ko) * 1994-07-08 2003-08-21 아스트라제네카 악티에볼라그 다단위정제투여형i
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound

Also Published As

Publication number Publication date
EP0652872B1 (en) 2000-11-08
AU6902494A (en) 1994-12-20
US5714504A (en) 1998-02-03
CN1055469C (zh) 2000-08-16
HU226824B1 (en) 2009-11-30
EP1020461B2 (en) 2015-10-21
SK282524B6 (sk) 2002-10-08
UA60289C2 (uk) 2003-10-15
LV11034A (lv) 1996-02-20
CN1110477A (zh) 1995-10-18
JP2004043493A (ja) 2004-02-12
ATE197452T1 (de) 2000-11-11
JP2004043494A (ja) 2004-02-12
ES2099047T3 (es) 2001-03-01
LTIP1941A (en) 1994-12-27
CN1259346A (zh) 2000-07-12
TNSN94058A1 (fr) 1995-04-25
LU91870I2 (fr) 2011-11-21
DK1020460T3 (da) 2009-08-10
SA05260103B1 (ar) 2010-01-31
LT3287B (en) 1995-06-26
GR970300012T1 (en) 1997-05-31
HK1008330A1 (en) 1999-05-07
SG49283A1 (en) 1998-05-18
RU95105587A (ru) 1996-10-27
JP3549111B2 (ja) 2004-08-04
KR950702553A (ko) 1995-07-29
CA2139653A1 (en) 1994-12-08
EP1020461A2 (en) 2000-07-19
EP0652872A1 (en) 1995-05-17
US6143771A (en) 2000-11-07
ES2326405T3 (es) 2009-10-09
US20100222591A1 (en) 2010-09-02
DK1020461T4 (en) 2016-02-15
DE652872T1 (de) 1997-09-04
DE69426254D1 (de) 2000-12-14
FI950377A (sv) 1995-01-27
DK0652872T3 (da) 2001-03-05
SK10195A3 (en) 1995-09-13
GR3035365T3 (en) 2001-05-31
NZ266915A (en) 1996-10-28
YU31494A (sh) 1997-05-28
JP4039999B2 (ja) 2008-01-30
WO1994027988A1 (en) 1994-12-08
SI9420002A (en) 1995-08-31
IS4161A (is) 1994-11-29
MA23210A1 (fr) 1994-12-31
JP3959056B2 (ja) 2007-08-15
NO307378B1 (no) 2000-03-27
DE69435220D1 (de) 2009-09-03
EE03157B1 (et) 1999-02-15
CZ20295A3 (en) 1995-10-18
EP1020460A2 (en) 2000-07-19
MY121192A (en) 2006-01-28
IS1854B (is) 2003-02-21
PL178994B1 (pl) 2000-07-31
CL2009000805A1 (es) 2009-08-21
EP1020460B1 (en) 2009-07-22
TW389761B (en) 2000-05-11
HRP940307B1 (en) 2001-06-30
HRP940307A2 (en) 1996-12-31
CA2337581A1 (en) 1994-12-08
IL109684A0 (en) 1994-12-29
NO2011009I1 (no) 2011-06-20
US20080312449A1 (en) 2008-12-18
IL109684A (en) 2002-05-23
SA94140756B1 (ar) 2006-05-20
YU49065B (sh) 2003-08-29
HUT71888A (en) 1996-02-28
JPH07509499A (ja) 1995-10-19
AU676337B2 (en) 1997-03-06
HK1028044A1 (en) 2001-02-02
DZ1785A1 (fr) 2002-02-17
DE69426254T2 (de) 2001-06-07
EP1020461B1 (en) 2009-07-22
PL307261A1 (en) 1995-05-15
PT1020460E (pt) 2009-07-29
US5693818A (en) 1997-12-02
KR100337274B1 (ko) 2003-12-31
SI22752A (sl) 2009-10-31
ES2326404T3 (es) 2009-10-09
NO950263L (no) 1995-01-24
ES2099047T1 (es) 1997-05-16
HU9500247D0 (en) 1995-03-28
ZA943557B (en) 1995-04-11
SI22752B (sl) 2010-01-29
ES2326405T5 (es) 2016-02-15
NO950263D0 (no) 1995-01-24
FI20070002A (sv) 2007-01-02
CY2224B1 (en) 2003-04-18
CN1107503C (zh) 2003-05-07
DK1020461T3 (da) 2009-08-10
DE69435221D1 (de) 2009-09-03
FI950377A0 (sv) 1995-01-27
PT652872E (pt) 2001-04-30
FI117755B (sv) 2007-02-15
PT1020461E (pt) 2009-07-29
CA2139653C (en) 2001-07-10
LV11034B (en) 1996-10-20
CZ287876B6 (cs) 2001-03-14
SI9420002B (sl) 2009-12-31
EP1020461A3 (en) 2006-10-04
RU2137766C1 (ru) 1999-09-20
EP1020460A3 (en) 2003-10-15
HK1028045A1 (en) 2001-02-02

Similar Documents

Publication Publication Date Title
SE9301830D0 (sv) New compounds
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis